VTRS Q3 2024 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.8B-4.8% YoY

Gross Profit

$1.5B38.9% margin

Operating Income

$226M6.0% margin

Net Income

$95M2.5% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

-1.2%

Cash Flow

Operating Cash Flow

$827M

Free Cash Flow

$741M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$44.8B

Total Liabilities

$25.0B

Stockholders' Equity

$19.8B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.9B	-4.8%
Gross Profit	$1.5B	$1.7B	-13.7%
Operating Income	$226M	$452M	-50.0%
Net Income	$95M	$332M	-71.4%

Revenue Segments

Brands

$2.4B63%

Generics

$1.4B37%

Geographic Segments

Developed Markets Segment

$2.3B61%

Greater China Segment

$562M15%

Emerging Markets Segment

$533M14%

Japan, Australia and New Zealand Segment

$344M9%